Coronavirus Latest News
UK firm to trial T-cell Covid vaccine that could give longer immunity
Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine
An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.
Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm’s chief executive and professor emeritus of molecular medicine at the University College London medical school.
Read the original article at The Guardian